256 related articles for article (PubMed ID: 25026275)
21. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL.
Sung B; Ravindran J; Prasad S; Pandey MK; Aggarwal BB
J Biol Chem; 2010 Nov; 285(46):35418-27. PubMed ID: 20837473
[TBL] [Abstract][Full Text] [Related]
22. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
23. Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL.
Bui HTT; Le NH; Le QA; Kim SE; Lee S; Kang D
Int J Med Sci; 2019; 16(11):1412-1423. PubMed ID: 31673231
[TBL] [Abstract][Full Text] [Related]
24. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
25. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress.
Zhou Y; Tian L; Long L; Quan M; Liu F; Cao J
PLoS One; 2013; 8(3):e58855. PubMed ID: 23536831
[TBL] [Abstract][Full Text] [Related]
26. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY; Jeon YK; Choi Y; Kim CW
Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
[TBL] [Abstract][Full Text] [Related]
27. AXL mediates TRAIL resistance in esophageal adenocarcinoma.
Hong J; Belkhiri A
Neoplasia; 2013 Mar; 15(3):296-304. PubMed ID: 23479507
[TBL] [Abstract][Full Text] [Related]
28. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
Zhu J; Zhou Q; Tan S
Cancer Lett; 2016 Dec; 383(2):154-160. PubMed ID: 27693456
[TBL] [Abstract][Full Text] [Related]
29. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
Khawaja H; Campbell A; Roberts JZ; Javadi A; O'Reilly P; McArt D; Allen WL; Majkut J; Rehm M; Bardelli A; Di Nicolantonio F; Scott CJ; Kennedy R; Vitale N; Harrison T; Sansom OJ; Longley DB; Evergren E; Van Schaeybroeck S
Cell Death Dis; 2020 Oct; 11(10):930. PubMed ID: 33122623
[TBL] [Abstract][Full Text] [Related]
30. Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.
Kojima Y; Nakayama M; Nishina T; Nakano H; Koyanagi M; Takeda K; Okumura K; Yagita H
J Biol Chem; 2011 Dec; 286(50):43383-93. PubMed ID: 22020938
[TBL] [Abstract][Full Text] [Related]
31. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
32. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
33. The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.
Sahu RP; Batra S; Kandala PK; Brown TL; Srivastava SK
Cancer Chemother Pharmacol; 2011 Feb; 67(2):481-7. PubMed ID: 20848283
[TBL] [Abstract][Full Text] [Related]
34. Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx.
Moon DO; Kang CH; Kang SH; Choi YH; Hyun JW; Chang WY; Kang HK; Koh YS; Maeng YH; Kim YR; Kim GY
Toxicol Appl Pharmacol; 2012 Feb; 259(1):87-95. PubMed ID: 22200406
[TBL] [Abstract][Full Text] [Related]
35. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
36. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
38. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.
Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K
Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623
[TBL] [Abstract][Full Text] [Related]
40. Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation.
Kim IY; Kang YJ; Yoon MJ; Kim EH; Kim SU; Kwon TK; Kim IA; Choi KS
Neuro Oncol; 2011 Mar; 13(3):267-79. PubMed ID: 21292685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
